Delving into the Latest Updates on Shanghai Minwei Biotechnology Co., Ltd with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Nervous System Diseases

Digestive System Disorders

Fusion protein

Synthetic peptide

Antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	10
Nervous System Diseases	2

Top 5 Drug Type	Count

Fusion protein	6
Synthetic peptide	2
Antibody	1
Antibody oligonucleotide conjugates	1
Monoclonal antibody	1

Top 5 Target	Count

FGF21R x GIPR x GLP-1R	2
GIPR x GLP-1R	2
GCGR x GIPR x GLP-1R	1
GIP x GLP-1	1

主要目的：初步评价不同剂量MWN101注射液相比于安慰剂、阳性对照药在2型糖尿病患者中的有效性。次要目的：评价不同剂量MWN101注射液相比于安慰剂、阳性对照药在2型糖尿病患者中的安全性、耐受性；评价MWN101注射液在2型糖尿病患者中的药代动力学/免疫原性特征。

[Translation]

Primary purpose: To preliminarily evaluate the effectiveness of different doses of MWN101 injection compared with placebo and positive control drugs in patients with type 2 diabetes. Secondary purpose: To evaluate the safety and tolerability of different doses of MWN101 injection compared with placebo and positive control drugs in patients with type 2 diabetes; To evaluate the pharmacokinetic/immunogenic characteristics of MWN101 injection in patients with type 2 diabetes.

Start Date26 Mar 2024

Sponsor / Collaborator

Shanghai Minwei Biotechnology Co., Ltd

CTR20240802 / Active, not recruitingPhase 2

评价MWN101注射液在非糖尿病的超重或肥胖受试者中的有效性、安全性及药代动力学特征的随机、双盲、安慰剂平行对照、多中心II期临床研究

[Translation] A randomized, double-blind, placebo-controlled, multicenter Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic characteristics of MWN101 injection in non-diabetic overweight or obese subjects

主要目的：初步评价不同剂量MWN101注射液相比于安慰剂在非糖尿病的超重或肥胖受试者中的有效性。次要目的：评价MWN101注射液在非糖尿病的超重或肥胖受试者中的安全性、耐受性及药代动力学/免疫原性特征。

[Translation]

Primary objective: To preliminarily evaluate the efficacy of different doses of MWN101 injection compared with placebo in non-diabetic overweight or obese subjects. Secondary objective: To evaluate the safety, tolerability and pharmacokinetic/immunogenicity characteristics of MWN101 injection in non-diabetic overweight or obese subjects.

Start Date25 Mar 2024

Sponsor / Collaborator

Shanghai Minwei Biotechnology Co., Ltd

CTR20231757 / CompletedPhase 1

评估MWN101注射液在中国健康志愿者中单、多次皮下给药的安全性、耐受性、药代动力学的随机、双盲、安慰剂对照、剂量递增Ia期临床研究

[Translation] A randomized, double-blind, placebo-controlled, dose-escalation Phase Ia clinical study to evaluate the safety, tolerability, and pharmacokinetics of MWN101 injection after single and multiple subcutaneous administration in healthy Chinese volunteers

主要目的：评估MWN101注射液在中国健康志愿者中单、多次给药的安全性、耐受性。次要目的：评估MWN101注射液在中国健康志愿者中单、多次给药的药代动力学。探索性目的：初步评估MWN101注射液在中国健康志愿者中的药效学。

[Translation]

Primary objective: To evaluate the safety and tolerability of MWN101 injection after single and multiple administrations in Chinese healthy volunteers. Secondary objective: To evaluate the pharmacokinetics of MWN101 injection after single and multiple administrations in Chinese healthy volunteers. Exploratory objective: To preliminarily evaluate the pharmacodynamics of MWN101 injection in Chinese healthy volunteers.

Start Date27 Jun 2023

Sponsor / Collaborator

Shanghai Minwei Biotechnology Co., Ltd

100 Clinical Results associated with Shanghai Minwei Biotechnology Co., Ltd

Login to view more data

0 Patents (Medical) associated with Shanghai Minwei Biotechnology Co., Ltd

Login to view more data

100 Deals associated with Shanghai Minwei Biotechnology Co., Ltd

Login to view more data

100 Translational Medicine associated with Shanghai Minwei Biotechnology Co., Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

8

Preclinical

IND Application

2

1

Phase 2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

MWN-101 ( GCGR x GIPR x GLP-1R )	Obesity More	Phase 2
MWN105 ( FGF21R x GIPR x GLP-1R )	Hyperlipidemias More	Preclinical
MWN-103 ( FGF21R x GIPR x GLP-1R )	Diabetes Mellitus, Type 2 More	Preclinical
MWN109 ( GIPR x GLP-1R )	Obesity More	Preclinical
MWX-201	Hyperlipidemias More	Preclinical